Biofourmis11.19.19
Biofourmis has reached an agreement to acquire Biovotion AG, a developer of a clinical-grade wearable biosensor platform. The acquisition includes the Everion biosensor and more than 60 global patents covering most of the wearable and sensor technology that exists for the arm or hand.
The acquisition of Biovotion enables Biofourmis to offer proprietary, clinical-grade wearables as part of its Biovitals ecosystem. Clinical-grade wearables are becoming integral across all areas of healthcare, offering continuous real-time physiological data formerly only available in clinical settings. Combining Biovotion’s wearables with Biofourmis’ digital therapeutics platform and its artificial intelligence (AI)-driven predictive analytics creates a comprehensive digital therapeutics solution.
The lead product among Biovotion’s wearables is the clinical-grade Everion device, which is a multi-sensor platform worn on the arm capable of measuring 22 parameters in real time. Collected physiological data can include heart rate, inter-beat interval, respiratory rate, blood oxygenation, skin temperature, and actigraphy (rest/activity cycles)—all gathered non-invasively. Additional clinical and non-clinical parameters such as blood pulse wave, motion intensity and steps, energy expenditure, sleep quality, and heart rate variability are also insights collected by Everion.
Everion rounds out Biofourmis’ Biovitals ecosystem, a personalized AI-powered predictive analytics platform that predicts clinical exacerbation in advance of a critical event. The multi-parameter physiology data captured from Everion will be an integral component of Biovitals digital therapeutics products and pipeline to manage conditions such as heart failure, COPD, oncology and pain.
“Biovotion had been a trusted partner for many years as we have leveraged each other’s technologies across numerous clinical, commercial, and research applications,” said Kuldeep Singh Rajput, CEO and founder of Biofourmis. “We are thrilled to add Everion to the Biovitals ecosystem, which will continue to help our clients achieve their goals such as demonstrating the value of pharmacotherapy, managing chronic diseases, predicting and preventing adverse events and improving clinical outcomes—and ultimately reducing healthcare costs.”
A Complete, Integrated Solution
The entire Biovotion team will be incorporated into the Biofourmis family under the name “Biofourmis AG” in Zürich, Switzerland. The team brings knowledge and insights for developing and launching clinical-grade wearables, as well as a roster of more than 80 current and previous partners—including AstraZeneca, Cleveland Clinic, Helios, IBM Research, Mayo Clinic, Microsoft, Novartis, and Penn Medicine.
“Our relationship with Biofourmis has been extremely beneficial over the years and in that time has grown in scope and depth, so joining forces made strategic sense for both our companies,” said Dr. Markus Christen, Biovotion chairman and CEO. “I am excited about what the future holds for our ground-breaking technology: Being part of the Biofourmis family will allow us to accelerate the development of our innovative platform to collect continuous vital data from patients. Certainly, providers, payers, managed care organizations and pharmaceutical companies will benefit tremendously from our synergies—but more importantly, this agreement will help more patients across the globe achieve optimal outcomes, which is most gratifying.”
Now that the Everion and Biovitals solutions are one, securing future clinical, pharmaceutical, and other agreements will be more efficient and expedited, offering potential clients a single, experienced and proven digital therapeutics partner for all their needs.
“Biofourmis’ powerful and predictive AI-driven Biovitals ecosystem is now complete with the addition of Biovotions’ high-fidelity, clinical-grade wearable Everion—and the extensive intellectual property for wearables and sensors that are part of this acquisition make Biofourmis the dominant player in this space,” Rajput said. “The combined solution sets a new standard for the emerging digital therapeutics market that creates a compelling competitive advantage.”
The acquisition of Biovotion enables Biofourmis to offer proprietary, clinical-grade wearables as part of its Biovitals ecosystem. Clinical-grade wearables are becoming integral across all areas of healthcare, offering continuous real-time physiological data formerly only available in clinical settings. Combining Biovotion’s wearables with Biofourmis’ digital therapeutics platform and its artificial intelligence (AI)-driven predictive analytics creates a comprehensive digital therapeutics solution.
The lead product among Biovotion’s wearables is the clinical-grade Everion device, which is a multi-sensor platform worn on the arm capable of measuring 22 parameters in real time. Collected physiological data can include heart rate, inter-beat interval, respiratory rate, blood oxygenation, skin temperature, and actigraphy (rest/activity cycles)—all gathered non-invasively. Additional clinical and non-clinical parameters such as blood pulse wave, motion intensity and steps, energy expenditure, sleep quality, and heart rate variability are also insights collected by Everion.
Everion rounds out Biofourmis’ Biovitals ecosystem, a personalized AI-powered predictive analytics platform that predicts clinical exacerbation in advance of a critical event. The multi-parameter physiology data captured from Everion will be an integral component of Biovitals digital therapeutics products and pipeline to manage conditions such as heart failure, COPD, oncology and pain.
“Biovotion had been a trusted partner for many years as we have leveraged each other’s technologies across numerous clinical, commercial, and research applications,” said Kuldeep Singh Rajput, CEO and founder of Biofourmis. “We are thrilled to add Everion to the Biovitals ecosystem, which will continue to help our clients achieve their goals such as demonstrating the value of pharmacotherapy, managing chronic diseases, predicting and preventing adverse events and improving clinical outcomes—and ultimately reducing healthcare costs.”
A Complete, Integrated Solution
The entire Biovotion team will be incorporated into the Biofourmis family under the name “Biofourmis AG” in Zürich, Switzerland. The team brings knowledge and insights for developing and launching clinical-grade wearables, as well as a roster of more than 80 current and previous partners—including AstraZeneca, Cleveland Clinic, Helios, IBM Research, Mayo Clinic, Microsoft, Novartis, and Penn Medicine.
“Our relationship with Biofourmis has been extremely beneficial over the years and in that time has grown in scope and depth, so joining forces made strategic sense for both our companies,” said Dr. Markus Christen, Biovotion chairman and CEO. “I am excited about what the future holds for our ground-breaking technology: Being part of the Biofourmis family will allow us to accelerate the development of our innovative platform to collect continuous vital data from patients. Certainly, providers, payers, managed care organizations and pharmaceutical companies will benefit tremendously from our synergies—but more importantly, this agreement will help more patients across the globe achieve optimal outcomes, which is most gratifying.”
Now that the Everion and Biovitals solutions are one, securing future clinical, pharmaceutical, and other agreements will be more efficient and expedited, offering potential clients a single, experienced and proven digital therapeutics partner for all their needs.
“Biofourmis’ powerful and predictive AI-driven Biovitals ecosystem is now complete with the addition of Biovotions’ high-fidelity, clinical-grade wearable Everion—and the extensive intellectual property for wearables and sensors that are part of this acquisition make Biofourmis the dominant player in this space,” Rajput said. “The combined solution sets a new standard for the emerging digital therapeutics market that creates a compelling competitive advantage.”
